^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 765049

    i
    Associations
    News

    Trials

    Company:
    Boehringer Ingelheim, Oxford BioTherap
    Drug class:
    CD3 agonist, B7-H6 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (NCT06091930)
    Phase 1
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    01/31/2024
    Primary completion :
    11/13/2026
    Completion :
    02/11/2027
    NCR3LG1
    |
    ezabenlimab (BI 754091) • BI 765049
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface (NCT04752215)
    Phase 1
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    05/06/2021
    Primary completion :
    12/23/2025
    Completion :
    12/31/2028
    NCR3LG1
    |
    ezabenlimab (BI 754091) • BI 765049